The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...

Biocon Biologics expands diabetes portfolio with US FDA approval of Kirsty, an interchangeable rapid-acting insulin aspart in US: Our Bureau, Bengaluru Wednesday, July 16, 2025, 1 ...

Biocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin ...

Biocon announced that its subsidiary, Biocon Biologics, has received US Food and Drug Administration (USFDA) approval for Kirsty (Insulin Aspart-xjhz) 100 units/ml, to improve glycemic control in ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...

Effective management of pediatric diabetes remains a clinical challenge, particularly due to the onset of lipodystrophy resulting from repeated insulin injections and inadequate rotation of injection ...

Insulin pumps are the most advanced insulin delivery technology available today for people with type 1 and type 2 diabetes. An insulin pump replaces injections with a syringe or insulin pen, using ...

As we move further away from the release of the Samsung Galaxy S25 Ultra, rumors about its successor, the Galaxy S26 Ultra, are starting to emerge more frequently.

If insulin glargine was prescribed, a vial was dispensed regardless of the treatment group because it was not available in a pen device at the start of the study.

The report includes historical data from 2023 to 2024 and forecasts until 2033. The insulin pen market in the United States has experienced remarkable growth over the last few years.